Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc., a developer of the immunotherapeutic agent pelareorep for cancer treatment, has announced its CEO’s participation in the NeauxCancer Conference in New Orleans. Here, they will provide a corporate overview and engage in one-on-one investor meetings. The event will also be webcasted live for broader accessibility.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
